| 11 whitepaper results |
|
-
The biobanking landscape is changing rapidly to deal with the increasing demands of the systems biology community. In 2012 Pharma IQ surveyed its global membership base about biobanking partnerships, overcoming bottlenecks and increasing investment levels. This information is invaluable if you use, or plan to use, biobanks in your medical research. learn more
biobank | biobanks | biobanking | global biobanking | biorepository | biobanking landscape | systems biology | UK Biobank | 20TB data | Professor Sir Rory Collins | medical research
-
The zebrafish is emerging as a complement to existing in vitro technologies and established preclinical in vivo models that can be scaled for high throughput. Technological innovation has helped the zebrafish embryo gain ground as a disease model and an assay system for drug screening. learn more
Zebrafish | Danio rerio | preclinical toxicity | preclinical toxicity testing | Biobide | transgenic lines | High Throughput Screening | animal model | toxicology | drug discovery | in vitro technologies | in vivo models
-
In this paper, a new direct nucleation control (DNC) approach is introduced that directly controls the apparent onset of nucleation defined as the formation of new particles with detectable size using in situ instruments. learn more
pharmaceutical crystallization processes | pharmaceutical crystallization | CSD | crystal size distribution | polymorphism | crystallisation | continuous crystallisation process
-
More than four-fifths of respondents claimed that the key issue they faced in the integration of sample information with discovery data was the challenge in merging analytics with physical and automation data. Around half of those questioned in the survey had a library or sample management team responsible for biological materials or samples. learn more
compound management | sample management | compound and sample management | sample information | discovery data | automation data | library management
-
Polymorphism and crystallisation are considered to be one of the most significant and demanding areas of pharmaceutical development. New discoveries have the potential to either give organisations a share of a crowded market place to great financial and reputational benefit or have hugely damaging repercussions, depending on at what stage the alternative crystallisation formation was discovered. learn more
polymorphism | crystallisation | drug development | Quality by Design
-
An interivew with Dr. Adam Friedman, Chief Resident at the Department of Dermatology at Albert Einstein College of Medicine, on sustained release of Nitric Oxcide from the Hybrid Nanoparticle Platform: A novel therapeutic strategy for cutaneus infections. learn more
Adam Friedman | pharma | cutaneus infections | Hybrid Nanoparticle Platform
-
Antimicrobial resistance has been an issue since the introduction into clinical use of the first agents in the 1940s. learn more
drug design | pharma | clinical trials | drug development | Antimicrobial resistance | JH Powers
-
Clinicians have noted an association between antimicrobial resistance and antimicrobial use since the introduction of these agents over 50 years ago. learn more
pharma | drug development | John Powers | resistance | antimicrobial agents
-
An Interview with Nachum Kaplan, Vice President of Microbiology at Affinium Pharmaceuticals on bacterial fatty-acid synthesis as a target for AFN-1252: a novel and selective-spectrum antibiotic for the treatment of Staphylococcal infection. learn more
-
Pseudomonas aeruginosa is one of the most dreaded Gramnegative bacterial pathogens in hospitals. Not only it is among the most frequently isolated Gram-negative organisms in bloodstream and wound infections, pneumonia, intra-abdominal-sepsis and urogenital-sepsis, but also it is frequently found in patients with comorbid illnesses and compromised by in-dwelling catheters, tubes and surgery where learn more
Anti-Pseudomonas | Pseudomonas | Malcolm GP Page | Jutta Heim | pharma
-
Rotavirus vaccines hold promise to decrease the burden of severe diarrhea in the poorest countries, where 85 percent of deaths due to rotavirus occur. learn more
live oral vaccines | Manish Patel | pharma | Andi L. Shane | Roger I. Glass | Rotavirus vaccines | Umesh D. Parashar | Baoming Jiang | Jon R. Gentsch
| 11 whitepaper results |
|
-
Global Pharmaceutical Distribution 2012
Venue to be Confirmed, Amsterdam, The Netherlands
September 18- 19, 2012 -
Cool Chain Logistics 2013
Congress Center Basel, Basel, Switzerland
January 28- 30, 2013 -
Information Governance & eDiscovery for Pharma, Biotech and Medical Devices
London, UK
June 26- 28, 2012 -
Cold Chain Global Forum 2012
Chicago, IL
September 24- 28, 2012
|
|
|
|
Subscribe by Email
|
Reach Pharma professionals through cost-effective marketing opportunities to deliver your message, position yourself as a thought leader, and introduce new products, techniques and strategies to the market.
Learn More >> Join today and interact with a vibrant network of pharma professionals, keeping up to date with the pharma industry by accessing our wealth of Pharma articles, videos, online seminars, live conferences and more. Sign Up Today! |
| Pharma IQ, a division of IQPC 2012 All rights reserved. Use of this site constitutes acceptance of our User Agreement and Privacy Policy. Careers With IQPC | Contact Us | Unsubscribe to Bizo | About Us |
|
Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!